Rhode Island S2109 prohibits health insurers and pharmacy benefit managers from reviewing prescriptions for opioid addiction treatment.

Rhode Island S2109 prohibits health insurers and pharmacy benefit managers from requiring or conducting reviews for prescription medicines used in the treatment of alcohol or opioid use disorder, specifically those containing methadone, buprenorphine, or naltrexone, or approved for managing opioid withdrawal symptoms. This act aims to ensure that these medications are accessible without unnecessary bureaucratic hurdles. The prohibition applies to health benefit plans issued or renewed after the act's effective date.

Rhode Island S2109 prohibits health insurers and pharmacy benefit managers from reviewing prescriptions for opioid addiction treatment.

Rhode Island S2109 prohibits health insurers and pharmacy benefit managers from requiring or conducting reviews for prescription medicines used in the treatment of alcohol or opioid use disorder, specifically those containing methadone, buprenorphine, or naltrexone, or approved for managing opioid withdrawal symptoms. This act aims to ensure that these medications are accessible without unnecessary bureaucratic hurdles. The prohibition applies to health benefit plans issued or renewed after the act's effective date.